ERBB2 and breast carcinoma: Firstly, it represents a significant proportion of breast cancer cases, around 45% to 55% [2], HER2 protein expression exists on a spectrum (IHC 0 to 3+), with HER2-low demonstrating intermediate molecular characteristics between HER2-zero and HER-2 positive tumors, which is a large patient population.